HOME >> MEDICINE >> NEWS
Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we woul
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
28-Apr-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
6. St. Jude scientist to lead NCI Pediatric Preclinical Testing Program
7. Testing drugs ability to reverse stroke after standard three-hour window has closed
8. Testing may one day pinpoint which early-stage cancer patients are at risk for relapse
9. Testing earlier for gestational diabetes a smarter way to screen pregnant women
10. Testing for alcohol problems in the workplace
11. UNC Researchers Testing First In New Class Of AIDS Drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2020)... ... February 21, 2020 , ... Dr. Stong, a leading ... for giving back. He has been a long-time volunteer with Healing the Children ... this particular HTC trip is to provide cleft lip and palate procedures to underprivileged ...
(Date:2/21/2020)... ... February 21, 2020 , ... Cosmetic surgery continues to grow ... Plastic Surgeons (ASPS). According to the ASPS, there were 17.7-million cosmetic procedures performed ... previous year. The American Society of Plastic Surgeons reported that some of the ...
(Date:2/20/2020)... ... ... R3 Stem Cell, the nation's leader in regenerative therapies and provider training, ... procedures on military veterans in 2019. The veterans traveled from all over the ... Cell Training Course for doctors , providers of all kinds learn how to perform ...
(Date:2/19/2020)... (PRWEB) , ... February 19, 2020 , ... ... at Advanced Periodontics and Dental Implant Center of Connecticut, celebrate 30 years of ... patients with the same low fees that they charged in 1989, only thirty ...
(Date:2/19/2020)... ... 19, 2020 , ... In 2017, the EU’s revamped Medical ... that currently govern medical device manufacturers under the Medical Devices Directive (MDD); the ... Major changes from the previous MDD include:, , Elimination ...
Breaking Medicine News(10 mins):
(Date:2/28/2020)... ... ... At the VA Maryland Health Care System, veterans can virtually meet with ... Video Connect application. Since its rollout in July 2019, the VA Video Connect app ... The VA Video Connect app has proven to be a special benefit for mental ...
(Date:2/26/2020)... PALO ALTO, Calif. (PRWEB) , ... February 26, ... ... autism in the world, and yet there is a worldwide scarcity of trained ... other special needs. Applied Behavioral Analysis (ABA) is an evidenced-based intervention that ...
(Date:2/23/2020)... N.C. (PRWEB) , ... February ... ... Oak Recovery has received a three-year accreditation by CARF International, the Commission ... of health and human services whose mission is to promote quality, value, ...
Breaking Medicine Technology:
Cached News: